From Bacterial Morphotypes to Phage Therapy: How Thomas Byrd’s Research Helped Shape the Fight Against Mycobacterium abscessus

For nearly two decades, Thomas Byrd, a physician-scientist at the University of New Mexico (UNM) School of Medicine, investigated the biology of a bacterium that was not yet widely recognised as a major clinical challenge. His research focused on Mycobacterium abscessus, a nontuberculous mycobacterium capable of causing difficult-to-treat pulmonary and extrapulmonary infections. At the time, the work was driven primarily by fundamental scientific questions about bacterial behaviour and pathogenicity. Today, as antimicrobial resistance increasingly limits treatment options, those early findings have acquired renewed significance, including in the development of bacteriophage-based approaches.

Thomas Byrd, MD, Emeritus Professor of Infectious Diseases at the University of New Mexico School of Medicine. His foundational research on Mycobacterium abscessus helped inform the development of phage-based therapeutic approaches. Photo: Jeff Sargent / UNM Health Sciences.

In a profile published on November 12, 2026, the University of New Mexico revisited Byrd’s research and its contribution to the growing interest in phage therapy against M. abscessus. The story illustrates how investigations into the fundamental biology of a pathogen can provide knowledge that becomes valuable years later, when new therapeutic strategies emerge.

M. abscessus belongs to the group of rapidly growing nontuberculous mycobacteria. It is particularly challenging to treat because of its intrinsic resistance to several antimicrobial agents, its capacity to acquire additional resistance mechanisms and its ability to persist in difficult clinical settings. Pulmonary infections are especially concerning in people with cystic fibrosis or other structural lung diseases, although the bacterium can also cause infections of the skin, soft tissues, joints and surgical wounds. Treatment generally requires prolonged combinations of antibiotics, which may have limited effectiveness and significant toxicity.

One of the most important contributions of Byrd and his collaborators came in 2006, when they published a study examining the relationship between bacterial morphology and virulence. The research, published in Microbiology, demonstrated that M. abscessus can switch between two distinct colony morphologies, commonly described as smooth and rough. These forms are not simply different appearances on a culture plate: they are associated with important differences in bacterial surface composition and behaviour.

The smooth morphotype is characterised by an abundant presence of glycopeptidolipids (GPLs) on the bacterial cell surface. These molecules contribute to properties such as sliding motility and biofilm formation. In contrast, rough variants contain substantially reduced amounts of GPLs and can develop characteristic serpentine cords, in which bacteria align end-to-end. This morphology has been associated with a more invasive and persistent phenotype.

The researchers demonstrated the biological significance of this transition using different bacterial variants. A smooth mutant derived from a clinical isolate was able to spontaneously revert to a rough morphology during serial passage. Importantly, this rough revertant regained the capacity to cause persistent, invasive infection in human monocytes and in the lungs of mice. The findings suggested that the ability to switch between smooth and rough forms could allow M. abscessus to move between a colonising phenotype and a more aggressive, invasive state.

The study therefore provided important insight into the relationship between the bacterial cell envelope, morphological variation and pathogenicity. It also highlighted the complexity of an organism whose behaviour cannot always be understood by examining a single strain or a single phenotype. This is particularly relevant when considering therapeutic approaches that depend on interactions between the bacterial surface and an antimicrobial agent.

Although the 2006 study did not investigate bacteriophages or directly identify phage receptors, its findings helped establish a broader understanding of the biological variability of M. abscessus. Such variability is relevant to phage therapy because bacteriophages must recognise and attach to specific structures on the bacterial surface before they can deliver their genetic material. Changes in surface composition can therefore influence the interactions between a phage and its bacterial host. Understanding the different phenotypes of M. abscessus is consequently an important part of developing strategies capable of targeting the pathogen in its different biological states.

Bacteriophages are viruses that specifically infect bacteria. In therapeutic applications, researchers generally seek lytic phages, which replicate inside susceptible bacterial cells and ultimately cause their destruction. However, identifying a phage capable of infecting a particular clinical isolate is not always straightforward. Phage susceptibility can vary considerably between bacterial strains, and resistance may emerge during treatment. In the case of M. abscessus, the complexity of the bacterial envelope and the diversity of clinical isolates make the identification of effective therapeutic phages particularly demanding.

The potential of this approach became more visible in 2019, when researchers reported the use of engineered bacteriophages to treat a patient with a disseminated, drug-resistant M. abscessus infection following lung transplantation. The treatment involved a combination of three mycobacteriophages, including genetically engineered phages, administered alongside conventional antimicrobial therapy. The report described clinical improvement and evidence of phage activity during treatment. Although the case demonstrated the feasibility of using engineered phages against a severe mycobacterial infection, the authors also emphasised the limitations of interpreting outcomes from an individual patient and the difficulty of separating the contribution of phages from that of other treatments.

Further evidence emerged in a 2022 study published in Cell, which described the treatment of a patient with severe cystic fibrosis-associated M. abscessus pulmonary infection using two engineered mycobacteriophages in combination with antibiotics. Molecular and metabolic analyses provided evidence of phage-induced bacterial lysis within days of treatment initiation. Radiological improvement was subsequently observed, and airway cultures became predominantly negative by day 118. The patient later underwent lung transplantation, and systematic examination of the explanted lungs did not detect M. abscessus. This report provided valuable information on the biological response of both the pathogen and the patient during treatment, while remaining a single-patient clinical observation rather than evidence of general therapeutic efficacy.

These cases illustrate how advances in mycobacteriophage isolation, genome engineering and personalised treatment have begun to expand the possibilities for managing infections that respond poorly to conventional antibiotics. Rather than relying exclusively on naturally occurring phages, researchers can modify certain bacteriophages to broaden their therapeutic potential, including by changing their host range or removing genetic elements associated with lysogeny. The development of phage cocktails may also help address bacterial diversity and reduce the likelihood that a single resistance mechanism will compromise treatment. Nevertheless, selecting an effective combination remains a complex process requiring detailed characterisation of the patient's bacterial isolate.

The clinical evidence, however, remains limited. A scoping review published in November 2026 examined the available literature on phage therapy for nontuberculous mycobacterial pulmonary disease. It identified five studies representing 20 unique patients, most of whom had infections involving drug-resistant M. abscessus. Reported outcomes were heterogeneous: some patients experienced microbiological or clinical improvement, while others showed limited or no measurable benefit. The authors concluded that current evidence supports the feasibility of phage therapy but is not sufficient to establish its efficacy. Larger, prospective studies and more standardised approaches will be needed to determine which patients are most likely to benefit.

This distinction is important when interpreting estimates of treatment success based on small numbers of compassionate-use cases. Phage therapy has produced encouraging results in individual patients, but these reports cannot yet provide a reliable estimate of its effectiveness across the wider population of people with M. abscessus infections. Questions concerning phage delivery, bacterial resistance, immune-mediated neutralisation, treatment duration and the optimal combination with antibiotics also remain active areas of investigation.

The University of New Mexico's profile of Thomas Byrd is therefore a reminder of the long-term value of fundamental microbiological research. The 2006 study did not develop a phage treatment, nor did it directly demonstrate that the two M. abscessus morphotypes respond differently to bacteriophages. Its contribution was to clarify how changes in bacterial surface composition are associated with changes in pathogenic behaviour. That knowledge forms part of the wider scientific foundation needed to understand this complex pathogen and to develop more targeted therapeutic strategies.

As phage therapy continues to attract attention as a potential response to antimicrobial resistance, the relationship between basic research and clinical innovation becomes increasingly apparent. Work that initially sought to explain an unusual bacterial phenotype has helped shape the scientific understanding of an organism that is now a major target for personalised antimicrobial approaches. For Byrd and his collaborators, the significance of those early investigations has continued to grow well beyond their original objectives.



References :

Howard, S. T., Rhoades, E., Recht, J., Pang, X., Alsup, A., Kolter, R., Lyons, C. R., and Byrd, T. F. (2006). “Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype.” Microbiology, 152, 1581–1590. https://doi.org/10.1099/mic.0.28625-0

Dedrick, R. M. et al. (2019). “Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus.” Nature Medicine. https://doi.org/10.1038/s41591-019-0437-z

“Case Study: Host and Pathogen Response to Bacteriophage Engineered Against Mycobacterium abscessus Lung Infection.” (2022). Cell, 185, 1860–1874.e12. https://doi.org/10.1016/j.cell.2022.04.024

Pais, M. et al. (2026). “Phage therapy for nontuberculous mycobacterial pulmonary disease: a scoping review.” Breathe, November 2026.

University of New Mexico Health Sciences Newsroom (November 12, 2026). “‘The Phages That Will Destroy’: How a UNM Researcher’s Work Paved the Way for Treating a Tough-to-Kill Bacterial Infection.”

Comments

Most Consulted Articles

Bacteriophages Disarm Inflammation-Associated E. coli Without Erasing the Gut Microbiome in IBD

🌐 PhageAtLabs® — a global interactive mapping of academic laboratories in phage research.

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

The Phage Therapy in the spotlight !

Phagos Launches CAPHARD, a 900-Million-Parameter AI Model to Predict Phage–Bacteria Interactions